Spontaneous regression of chemotherapy-refractory non-Hodgkin's lymphoma preceding the development of secondary leukaemia.

abstract：:According to the International Workshop on Chronic Lymphocytic Leukemia/National Institutes of Health (iwCLL/NIH) guidelines for the diagnosis and treatment of chronic lymphocytic leukemia (CLL), bone marrow biopsy (BMB) is not required at diagnosis, however recommended before initiating treatment. That notwithstandin...

journal_title：Leukemia & lymphoma

authors： Baliakas P,Kanellis G,Stavroyianni N,Fameli M,Anagnostopoulos A,Stamatopoulos K,Papadaki T

更新日期：2013-11-01 00:00:00

abstract：:The aberrant expression of myeloid antigen CD66 on acute B-lymphoblastic leukemia (B-ALL) cells is a well-documented phenomenon. CD66a is a major subtype of the CD66 family which plays a dual role in different cancers, and the contradictory effect may depend on the isoform ratio of CD66a-4L to CD66a-4S. Although the a...

journal_title：Leukemia & lymphoma

authors： Zhao W,Zhang Y,Liu D,Zhong L,He Q,Zhao Y

更新日期：2015-01-01 00:00:00

abstract：:Following the introduction of the WHO classification of chronic myeloproliferative disorders (MPDs), after approximately 5 years, a critical reappraisal appears to be warranted. Retrospective clinico-pathological evaluations conducted in the meantime, as well as the detection of new biomarkers, may aid in testing the ...

journal_title：Leukemia & lymphoma

authors： Thiele J,Kvasnicka HM

更新日期：2006-03-01 00:00:00

abstract：:Bortezomib and gemcitabine have each shown activity as single agents in mantle cell lymphoma (MCL), which is incurable. The purpose of this phase II study was to determine the efficacy and safety of the previously unstudied combination of bortezomib and gemcitabine in patients with relapsed or refractory MCL. Patients...

journal_title：Leukemia & lymphoma

authors： Kouroukis CT,Fernandez LA,Crump M,Gascoyne RD,Chua NS,Buckstein R,Turner R,Assouline S,Klasa RJ,Walsh W,Powers J,Eisenhauer E

更新日期：2011-03-01 00:00:00

abstract：:A heterogeneous group of malignancies are associated with Epstein-Barr virus (EBV) infection. These malignancies arise in both immunosuppressed and immunocompetent individuals and can be divided into three patterns of latency depending on the viral genes that are expressed. In Type III latency malignancies, such as po...

journal_title：Leukemia & lymphoma

authors： Cohen JI,Bollard CM,Khanna R,Pittaluga S

更新日期：2008-01-01 00:00:00

abstract：:Cytogenetic deletions on the short arm of chromosome 12 are common, recurring alterations found in a wide range of hematological neoplasias, including childhood acute lymphoblastic leukemia (ALL), the most frequent pediatric malignancy. This loss of genetic material suggests the presence of a tumor suppressor gene pla...

journal_title：Leukemia & lymphoma

authors： Aïssani B,Bonan C,Baccichet A,Sinnett D

更新日期：1999-07-01 00:00:00

abstract：:The transcriptional factor SOX11 is a disease-defining antigen in mantle cell lymphoma (MCL) and absent in most non-malignant tissues. To explore the role of SOX11-related cell signaling, and potentially take benefit from these for targeted therapy, associated networks and proteins need to be defined. In this study, w...

journal_title：Leukemia & lymphoma

authors： Kuci V,Nordström L,Conrotto P,Ek S

更新日期：2016-08-01 00:00:00

abstract：:This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE...

journal_title：Leukemia & lymphoma

authors： Hu B,Younes A,Westin JR,Turturro F,Claret L,Feng L,Fowler N,Neelapu S,Romaguera J,Hagemeister FB,Rodriguez MA,Samaniego F,Fayad LE,Copeland AR,Nastoupil LJ,Nieto Y,Fanale MA,Oki Y

更新日期：2018-04-01 00:00:00

abstract：:Infant acute leukemia, known to have a poor outcome with conventional therapy, usually has a molecular rearrangement at chromosome band 11q23. The 11q23 translocation partner is typically at 4q21 in infant ALL, but other 11q23 translocation partners occur in infant ALL and AML. The MLL gene at 11q23, and the AF4 gene ...

journal_title：Leukemia & lymphoma

authors： Hilden JM,Frestedt JL,Kersey JH

更新日期：1997-04-01 00:00:00

abstract：:Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We desig...

journal_title：Leukemia & lymphoma

authors： Shin SH,Kim YJ,Lee D,Cho D,Ko YH,Cho J,Park WY,Park D,Kim SJ,Kim WS

更新日期：2019-09-01 00:00:00

abstract：:ZAP-70 has emerged as a protein of potential prognostic importance in chronic lymphocytic leukemia (CLL) following gene expression profiling which compared the 2 well established prognostic sub-sets, those with unmutated and mutated IgVH genes. This protein tyrosine kinase (PTK), known to be of importance in T and NK ...

journal_title：Leukemia & lymphoma

authors： Orchard J,Ibbotson R,Best G,Parker A,Oscier D

更新日期：2005-12-01 00:00:00

abstract：:Isolated central nervous system involvement in Richter's syndrome (RS) is extremely rare and only 6 such cases have been described, so far. We report a 60-year-old woman with B-cell chronic lymphocytic leukemia (B-CLL) heavily pretreated with cladribine based regimens and rituximab in whom RS in the brain was first ma...

journal_title：Leukemia & lymphoma

authors： Robak T,Góra-Tybor J,Tybor K,Jamroziak K,Robak P,Kordek R,Rieske P,Majos A,Urbańska-Ryś H

更新日期：2004-06-01 00:00:00

abstract：:Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare variant of Hodgkin's lymphoma (HL) in children. Since specific immunohistochemical staining has become available, NLPHL can be separated from classical Hodgkin's lymphoma (cHL) more accurately. Scarce information is available about pediatric NLPHL tre...

journal_title：Leukemia & lymphoma

authors： van Grotel M,Lam KH,de Man R,Beishuizen A,Pieters R,van den Heuvel-Eibrink MM

更新日期：2006-08-01 00:00:00

abstract：:Although BCR-ABL is the hallmark genetic abnormality of chronic myeloid leukemia (CML), secondary molecular events responsible for the evolution of the disease to blast crisis are yet to be deciphered. Taking into account the significant association of ecotropic viral integration site I (EVI1) in CML drug resistance, ...

journal_title：Leukemia & lymphoma

authors： Kuila N,Nayak KB,Halder A,Agatheeswaran S,Biswas G,Biswas S,Pattnayak NC,Chakraborty S

更新日期：2017-08-01 00:00:00

abstract：:Ninety-nine patients with "standard risk" Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one patients (21%) relapsed, 17 of whom (81%) obtained a second complete remission. The projected 9-year overall survi...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Barbieri E,Gherlinzoni F,Frezza G,Mazza P,Pica A,Ammendolia I,Bendandi M,Neri S,Miniaci G

更新日期：1994-04-01 00:00:00

abstract：:Autocrine Motility Factor (AMF)/maturation factor (MF)/neuroleukin (NLK) is a multifunctional protein, which acts as a glucose 6-phosphate isomerase (G6PI) intracellularly. Exto-G6PI stimulates invasion and metastasis of tumor cells, neurotropic growth and differentiation of leukemic cells. The cell motility and proli...

journal_title：Leukemia & lymphoma

authors： Haga A,Komazaki S,Funasaka T,Hashimoto K,Yokoyama Y,Watanabe H,Raz A,Nagase H

更新日期：2006-10-01 00:00:00

abstract：:The patient granulocyte-colony stimulating factor (G-CSF) response is represented by the leukocyte peak in the blood induced by a single dose of G-CSF after chemotherapy, and is correlated with subsequent neutropenic infection risk. General patterns for a meaningful risk group stratification, have not yet been determi...

journal_title：Leukemia & lymphoma

authors： Straka C,Salwender H,Schnabel B,Sandherr M,Wandt H,Hübel K,Scheid C,Metzner B,Hentrich M,Franke D,Weidenegger G,Freund M,Sezer O,Einsele H,Hinke A,Emmerich B

更新日期：2015-02-01 00:00:00

abstract：:P53 protein expression in malignant cells of five patients with Burkitt lymphoma (BL) and from two patients with B-cell acute lymphoblastic leukemia (B-ALL) was examined with anti p53 protein monoclonal antibodies PAb1801, PAb240 and p53-D07 using an immunocytochemical technique. Four of the seven patients were positi...

journal_title：Leukemia & lymphoma

authors： Nagai J,Kigasawa H,Koga N,Katoh A,Nishihira H,Nagao T

更新日期：1998-02-01 00:00:00

abstract：:131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia (CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN gamma. In study, 1, 13 not pretreated and 41 pretreated patients, 48 in chronic phase disease, 6 in accelerated phase, received 4 x 10(6) U/m2 IFN a...

journal_title：Leukemia & lymphoma

authors： Niederle N,Kloke O,Wandl UB,Becher R,Moritz T,Opalka B

更新日期：1993-01-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of the elderly that carry an increased risk of progression to acute myeloid leukemia (AML). Since small non-coding RNAs (sRNAs), including microRNA (miRNAs), act as regulators of cellular differentiation, we hypothesized that changes to sRNAs might be ...

journal_title：Leukemia & lymphoma

authors： Guo Y,Strickland SA,Mohan S,Li S,Bosompem A,Vickers KC,Zhao S,Sheng Q,Kim AS

更新日期：2017-09-01 00:00:00

abstract：:CD95 (Fas/Apo-1) mediates apoptosis in cells of various types. Expression of CD95 and its function were investigated in myeloma cells and most plasma cell lines have been found to be CD95-positive. Anti-CD95 antibody induced apoptosis in these cell lines in a manner dependent on intensity of CD95 expression. Bel-2 exp...

journal_title：Leukemia & lymphoma

authors： Hata H,Matsuzaki H,Takeya M,Takatsuki K

更新日期：1996-12-01 00:00:00

abstract：:Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone),...

journal_title：Leukemia & lymphoma

authors： Borchmann P,Herbrecht R,Wilhelm M,Morschhauser F,Hess G,Cernohous P,Veals SA,Singer JW,Engert A

更新日期：2011-04-01 00:00:00

abstract：:A growing body of evidence indicates that long non-coding RNA (lncRNA) is involved in the development and progression of many diseases. It has been reported that lncRNA LINC00467 is disregulated in multiple tumors, while its role in acute myeloid leukemia (AML) is still unknown. Here, we find that LINC00467 expression...

journal_title：Leukemia & lymphoma

authors： Lu J,Wu X,Wang L,Li T,Sun L

更新日期：2020-10-15 00:00:00

abstract：:Hepatocyte growth factor (HGF) was identified, purified and molecularly cloned as a potent mitogen for mature rat hepatocytes in primary culture. It is one of the largest cytokines and is composed of disulfide-linked subunits of approximately 60 (heavy chain) and 35 kilodaltons (light chain). Recent observations revea...

journal_title：Leukemia & lymphoma

authors： Gohda E,Nakamura S,Yamamoto I,Minowada J

更新日期：1995-10-01 00:00:00

abstract：:We report results of a randomized, phase III study of ofatumumab versus physicians' choice treatment in patients with bulky fludarabine-refractory chronic lymphocytic leukemia and explore extended versus standard-length ofatumumab treatment. Patients (79 ofatumumab, 43 physicians' choice) completed a median 6 (ofatumu...

journal_title：Leukemia & lymphoma

authors： Österborg A,Udvardy M,Zaritskey A,Andersson PO,Grosicki S,Mazur G,Kaplan P,Steurer M,Schuh A,Montillo M,Kryachok I,Middeke JM,Kulyaba Y,Rekhtman G,Gorczyca M,Daly S,Chang CN,Lisby S,Gupta I

更新日期：2016-09-01 00:00:00

abstract：:The humanized monoclonal antibody Hu1D10 (Remitogen, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of human leukocyte antigen-DR expressed on the majority of B-cell lymphomas and on normal B cells of most individuals. Hu1D10 mediates complement-mediated cytotoxicity, antibody-dependent cell-me...

journal_title：Leukemia & lymphoma

authors： Shi JD,Bullock C,Hall WC,Wescott V,Wang H,Levitt DJ,Klingbeil CK

更新日期：2002-06-01 00:00:00

abstract：:Apoptosis, the caspase-mediated cell death, plays an important role in the etiology, pathogenesis and therapy of a variety of diseases. Abnormalities of apoptosis regulation, resulting in either its inhibition or enhancement, play a key role in the development of various malignant hematological disorders. Several rout...

journal_title：Leukemia & lymphoma

authors： Smolewski P,Darzynkiewicz Z,Robak T

更新日期：2003-07-01 00:00:00

abstract：:One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years. The patient pop...

journal_title：Leukemia & lymphoma

authors： Mi Y,Xue Y,Yu W,Liu S,Zhao Y,Meng Q,Bian S,Wang J

更新日期：2008-03-01 00:00:00

abstract：:Secondary malignancies represent a relevant complication of chemotherapy employed for a previous cancer. Acute leukemias represent the most frequent secondary malignancy in the first decade following primary neoplasms; secondary leukemias are generally myeloid and can be preceeded by a myelodysplastic syndrome. The bi...

journal_title：Leukemia & lymphoma

authors： Pagano L,Pulsoni A,Mele L,Leone G

更新日期：2000-11-01 00:00:00

abstract：:Myeloablative doses of busulfan (Bu) with fludarabine (Flu) have reduced toxicity, however, limited by an increased relapse rate. We aimed to improve outcome of Flu-Bu regimen by augmentation with thiotepa (TT) (10 mg/kg). Eighty-nine patients with AML, 44 patients conditioned with Flu-Bu (group 1), and 45 patients au...

journal_title：Leukemia & lymphoma

authors： Sheth V,Nachmias B,Grisariu S,Avni B,Or R,Shapira M

更新日期：2019-03-01 00:00:00